Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luis Baez

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Cancer Medicine|January 21, 2020
A randomized trial of nurse-administered behavioral interventions to manage anticipatory nausea and vomiting in chemotherapyJonathan J Hunter, Robert G Maunder, Dawen Sui, et al.
Clinical Breast Cancer|October 10, 2022
Smoking and Radiation-induced Skin Injury: Analysis of a Multiracial, Multiethnic Prospective Clinical TrialRyan T Hughes, Edward H Ip, James J Urbanic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2018
Association Between Inflammatory Biomarker C-Reactive Protein and Radiotherapy-Induced Early Adverse Skin Reactions in a Multiracial/Ethnic Breast Cancer PopulationJennifer J Hu, James J Urbanic, L Doug Case, et al.
JNCI Cancer Spectrum|August 11, 2021
<i>MAF</i> Amplification and Adjuvant Clodronate Outcomes in Early-Stage Breast Cancer in NSABP B-34 and Potential Impact on Clinical PracticeAlexander H G Paterson, Peter C Lucas, Stewart J Anderson, et al.
Cancer|August 9, 2017
Double-blind, randomized phase 3 trial of low-dose 13-cis retinoic acid in the prevention of second primaries in head and neck cancer: Long-term follow-up of a trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590)Aarti K Bhatia, Ju-Whei Lee, Harlan A Pinto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2021
Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance)Andrew B Nixon, Alexander B Sibley, Yingmiao Liu, et al.
Breast Cancer Research and Treatment|March 1, 2022
Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)Charles E Geyer, Hanna Bandos, Priya Rastogi, et al.
Breast Cancer Research and Treatment|March 22, 2023
Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41Priya Rastogi, Gong Tang, Saima Hassan, et al.
Breast Cancer Research and Treatment|February 3, 2022
Behavioral and health outcomes from the NRG Oncology/NSABP B-36 trial comparing two different adjuvant therapy regimens for early-stage node-negative breast cancerPatricia A Ganz, Hanna Bandos, Charles E Geyer, et al.
The Lancet. Oncology|August 15, 2015
Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trialHarry D Bear, Gong Tang, Priya Rastogi, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Cancer Medicine|January 21, 2020
A randomized trial of nurse-administered behavioral interventions to manage anticipatory nausea and vomiting in chemotherapyJonathan J Hunter, Robert G Maunder, Dawen Sui, et al.
Clinical Breast Cancer|October 10, 2022
Smoking and Radiation-induced Skin Injury: Analysis of a Multiracial, Multiethnic Prospective Clinical TrialRyan T Hughes, Edward H Ip, James J Urbanic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2018
Association Between Inflammatory Biomarker C-Reactive Protein and Radiotherapy-Induced Early Adverse Skin Reactions in a Multiracial/Ethnic Breast Cancer PopulationJennifer J Hu, James J Urbanic, L Doug Case, et al.
JNCI Cancer Spectrum|August 11, 2021
<i>MAF</i> Amplification and Adjuvant Clodronate Outcomes in Early-Stage Breast Cancer in NSABP B-34 and Potential Impact on Clinical PracticeAlexander H G Paterson, Peter C Lucas, Stewart J Anderson, et al.
Cancer|August 9, 2017
Double-blind, randomized phase 3 trial of low-dose 13-cis retinoic acid in the prevention of second primaries in head and neck cancer: Long-term follow-up of a trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590)Aarti K Bhatia, Ju-Whei Lee, Harlan A Pinto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2021
Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance)Andrew B Nixon, Alexander B Sibley, Yingmiao Liu, et al.
Breast Cancer Research and Treatment|March 1, 2022
Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)Charles E Geyer, Hanna Bandos, Priya Rastogi, et al.
Breast Cancer Research and Treatment|March 22, 2023
Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41Priya Rastogi, Gong Tang, Saima Hassan, et al.
Breast Cancer Research and Treatment|February 3, 2022
Behavioral and health outcomes from the NRG Oncology/NSABP B-36 trial comparing two different adjuvant therapy regimens for early-stage node-negative breast cancerPatricia A Ganz, Hanna Bandos, Charles E Geyer, et al.
The Lancet. Oncology|August 15, 2015
Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trialHarry D Bear, Gong Tang, Priya Rastogi, et al.
Pageof 3